Comparative Pharmacology
Head-to-head clinical analysis: CLARINEX D 12 HOUR versus PBZ SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARINEX D 12 HOUR versus PBZ SR.
CLARINEX-D 12 HOUR vs PBZ-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.
Antihistamine; H1-receptor antagonist that competes with histamine for binding at H1 receptor sites, thereby preventing histamine-mediated allergic responses.
1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.
100-200 mg orally every 12 hours; maximum 400 mg/day.
None Documented
None Documented
Desloratadine: 27 hours (terminal), allows once-daily dosing; pseudoephedrine: 4-6 hours (prolonged in alkaline urine).
Terminal elimination half-life is approximately 4-6 hours in adults with normal renal function; clinically relevant dosing every 4-6 hours is recommended.
Desloratadine: 40.2% renal (unchanged and metabolites), 41.7% fecal; pseudoephedrine: 70-90% renal (unchanged).
Primarily renal excretion (80-90% as unchanged drug) via glomerular filtration and tubular secretion. Biliary/fecal excretion accounts for approximately 5-10%.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine